Amryt Pharma Plc (NASDAQ: AMYT)

Engel Law PLLC is investigating whether fair value to Amryt shareholders will result from the proposed sale of Amryt Pharma Plc (NASDAQ: AMYT) to Chiesi Farmaceutici S.p.A. for $14.50 per ADS, plus Contingent Value Rights of up to an additional $2.50 per ADS.

The Firm’s investigation concerns:

(i) whether Amryt’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration ($14.50 per ADS, plus Contingent Value Rights of up to an additional $2.50 per ADS) adequately compensates Amryt’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Amryt Pharma Plc

Address
MM slash DD slash YYYY
Consent(Required)